VA06
VA06 is a derivative of QS-21 (HY-101092A) that retains potent adjuvant activity while significantly reducing toxicity. VA06 self-assembles into flexible worm-like micelles with continuously elongated nanostructures and enhanced drug-loading encapsulation capacity. VA06 induces antigen-specific antibody production, enhances the secretion of TNF-α, IFN-γ and IL-2 in CD4+ and CD8+ T cells, and promotes the expression of immune-related and antiviral-related genes in mature dendritic cells. VA06 does not require liposome formulation, which simplifies production and storage processes. VA06 can be used in the research of varicella-zoster virus infection and Mycobacterium tuberculosis infection.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- 화학식: C63H103NO20
- 분자량:1194.49
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Biological Activity
VA06 (0.5 mM; 1 min) in PBS solvent self-assembles into flexible wormlike micelles with continuous, elongated nanostructures[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
The VA06+MPL (BST02) formulation (5 μg VA06 + 5 μg MPL per dose; subcutaneous injection; administered on day 0 and day 14) induces robust VZV-gE-specific humoral and cellular immune responses in female C57BL/6J mice[1].
VA06 (5 μg per mouse; intramuscular injection; single administration) exhibits excellent in vivo muscle tolerance in male rats, with no reactogenicity detected[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (female, 6-8 weeks of age)[1]
-
Dosage:5 μg VA06 + 5 μg MPL per dose
-
Administration:s.c.; Day 0 and Day 14
-
Result:Induced anti-OVA IgG titers of ≥1×1011 ng/mL, anti-OVA IgG1 titers of ≥1×109 ng/mL, and anti-OVA IgG2b titers of ≥1×106 ng/mL.
Induced 3.5% of CD4+ lymphocytes to produce TNF-α, 3% of CD4+ lymphocytes to produce IL-2, and 1.75% of CD8+ lymphocytes to produce TNF-α.\n
Induced VZV-gE-specific IgG, IgG1, IgG2c, and IgG2b antibody levels significantly higher than PBS control, with IgG levels slightly higher than AS01b.
Induced 2.75% of CD4+ lymphocytes to produce IFN-γ and 3% of CD4+ lymphocytes to produce TNF-α, and 1% of CD8+ lymphocytes to produce IFN-γ.
-
Animal Model:C57BL/6J (female, 6-8 weeks of age)[1]
-
Dosage:5 μg VA06 + 5 μg MPL per dose
-
Administration:s.c.; two doses, 2 weeks apart
-
Result:Induced Mtb-M72-specific IgG, IgG1, IgG2b, and IgG2c antibody levels significantly higher than PBS control and QS-21+MPL group, with IgG, IgG1, IgG2b, and IgG2c levels higher than BST01.
Induced 3.5% of CD4+ lymphocytes to produce IFN-γ, 3% of CD4+ lymphocytes to produce TNF-α, and 1.25% of CD8+ lymphocytes to produce IFN-γ (all significantly higher than QS-21+MPL and BST01 groups).
-
Animal Model:Male rats[1]
-
Dosage:5 μg VA06
-
Administration:intramuscular; single dose
-
Result:Showed no detectable reactogenicity or muscle tissue damage (tissue morphology comparable to PBS control and AS01b groups, and significantly less damage than QS-21+MPL group).
Chemical Information
-
분자량 1194.49
-
화학식 C63H103NO20
-
SMILES
O[C@H]1[C@]2(C(O[C@H]3[C@H](O[C@@H]4O[C@@H](C)[C@H](O[C@H]5[C@H](O)[C@@H](O)[C@H](O)CO5)[C@@H](O)[C@H]4O)[C@@H](O)[C@@H](NC(CCCCCCCCCCCCCCC(O)=O)=O)[C@@H](CO)O3)=O)[C@@H](CC(C)(C)CC2)C6=CC[C@@]7([H])[C@@]([C@]6(C)C1)(C)CC[C@@]8([H])[C@](C)(C=O)[C@@H](O)CC[C@@]87C
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
VA06 Related Classifications
HY-182369 Related Classifications
Powered by Bioz